Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
NeXT Personal® Dx is a tumor-informed molecular residual disease (MRD) liquid biopsy with ultra-high sensitivity and specificity. Leveraging whole-genome sequencing (WGS), advanced bioinformatics, and comprehensive personalized signatures based on up to 1800 variants, NeXT Personal® Dx achieves industry-leading performance to empower earlier insights that can shape the trajectory of cancer care.1,2
Reach out to Order Now
Leverage WGS-based personalized signatures that target up to ~1800 variants
Detect MRD earlier at lower levels with an assay that can detect circulating tumor DNA (ctDNA) down to ~1 Parts Per Million (PPM)
Minimize false-positives while maximizing the tumor signature with our proprietary technology
NeXT Personal Dx may aid in a multitude of clinical use cases, from risk stratification for adjuvant treatment to early detection of recurrence.
Our world-class CAP/CLIA ISO 13485-2016 lab operates 24/7, enabling fast turnaround time.
NeXT Personal® Dx reports include qualitative and quantitative readouts for the current timepoint as well as longitudinal data.
NeXT Personal® Dx delivers exceptional performance even with small samples. Tissue and blood samples are required for the initial test to design the tumor-informed panel. Subsequent tests only require blood samples.
Whole genome sequencing (WGS) of tumor and matched-normal blood sample performed.
Up to 1800 variants selected for each molecular residual disease (MRD) signature from Whole Genome.
Tumor-informed personalized panel created for each patient.
ctDNA in each plasma timepoint tracked and quantified using optimized signal-to-noise ratio.
Personalis is a leader in tissue WGS, leveraging NeXT SENSE™ technology for ultra-sensitive and patient-specific panels.
NeXT Personal® Dx uses whole-genome sequencing on tumor and normal samples to identify more tumor-specific variants, which makes it possible to design ultra-sensitive personalized tumor signatures based on up to 1,800 variants. Targeting more variants, including those not found in coding regions, allows the assay to detect MRD at extremely low tumor fractions or under challenging conditions. Our proprietary NeXT SENSE™ (Signal Enhancement and Noise Suppression Engine) technology is leveraged across the workflow to achieve ultra-high specificity.
NeXT Personal Dx is currently available for patients with solid tumors. The test is not suitable for blood cancers, such as leukemia and lymphomas.
No, NeXT Personal Dx is intended to complement standard imaging techniques for monitoring patients, and is not designed to replace cancer screening tests, such as mammograms, colonoscopies, and other screening tests. This test is specifically used for monitoring patients who have already been diagnosed with cancer and are undergoing treatment or follow-up care.
NeXT Personal Dx enables higher sensitivity with detection down to ~1 PPM (parts per million of ctDNA) with high specificity (greater than >99.9%).1 This can potentially lead to earlier detection of recurrent cancer.
Coverage for NeXT Personal Dx varies depending on a patient’s insurance plan. Personalis works with insurance providers to secure coverage for eligible patients. Personalis also offers a financial assistance program for qualifying patients.
Track cancer with ultra-sensitive molecular residual disease (MRD) testing using NeXT Personal Dx.
New data presented at ASCO 2024 in Breast Cancer and Advanced Stage Pan-Cancer cohort on immunotherapy
An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma
Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics
Analytical performance of an ultra-sensitive, tumor-informed liquid biopsy platform for molecular residual disease detection and clinical guidance
PRO-1070-v3
This test is a laboratory developed test (LDT) and is performed in the CAP accredited, CLIA-certified Personalis Clinical Laboratory. The test was developed, and its performance characteristics determined by the Personalis Clinical Laboratory. It has not been cleared or approved by the United States Food and Drug Administration (FDA).
